Carisma to develop allogeneic macrophage therapies

By The Science Advisory Board staff writers

April 26, 2021 -- Carisma Therapeutics has established a multiyear scientific collaboration with Dr. Bruce Blazar of the University of Minnesota to investigate and develop allogeneic macrophage therapies.

The company is interested in expanding the potential benefits of its proprietary chimeric antigen receptor (CAR)-macrophage (CAR-M) platform beyond oncology and into other disease states with unmet clinical needs.

The collaboration with Blazar represents the start of the development of allogeneic, universal donor-derived monocyte and macrophage cell therapies at Carisma, according to Michael Klichinsky, PhD, scientific co-founder and senior vice president of research at Carisma.

The focus of the partnership will be to optimize and develop induced pluripotent stem cell (iPSC)-derived allogeneic chimeric antigen receptor macrophages, which should further expand the potential of macrophage-based cell therapy for cancer and other diseases.

Financial details of the collaboration were not disclosed.

Leukemia & Lymphoma Society support next-gen cell therapies
The Leukemia & Lymphoma Society Therapy Acceleration Program announced five new investments aimed at speeding the development of new and improved...
Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and...
Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration....

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter